Biased GPCR signaling: Possible mechanisms and inherent limitations
- PMID: 32201315
- PMCID: PMC7275904
- DOI: 10.1016/j.pharmthera.2020.107540
Biased GPCR signaling: Possible mechanisms and inherent limitations
Erratum in
-
Corrigendum to "Biased GPCR signaling: Possible mechanisms and inherent limitations" [Pharmacology & Therapeutics 211 (2020) 107540].Pharmacol Ther. 2020 Sep;213:107615. doi: 10.1016/j.pharmthera.2020.107615. Epub 2020 Jul 2. Pharmacol Ther. 2020. PMID: 32622639 No abstract available.
Abstract
G protein-coupled receptors (GPCRs) are targeted by about a third of clinically used drugs. Many GPCRs couple to more than one type of heterotrimeric G proteins, become phosphorylated by any of several different GRKs, and then bind one or more types of arrestin. Thus, classical therapeutically active drugs simultaneously initiate several branches of signaling, some of which are beneficial, whereas others result in unwanted on-target side effects. The development of novel compounds to selectively channel the signaling into the desired direction has the potential to become a breakthrough in health care. However, there are natural and technological hurdles that must be overcome. The fact that most GPCRs are subject to homologous desensitization, where the active receptor couples to G proteins, is phosphorylated by GRKs, and then binds arrestins, suggest that in most cases the GPCR conformations that facilitate their interactions with these three classes of binding partners significantly overlap. Thus, while partner-specific conformations might exist, they are likely low-probability states. GPCRs are inherently flexible, which suggests that complete bias is highly unlikely to be feasible: in the conformational ensemble induced by any ligand, there would be some conformations facilitating receptor coupling to unwanted partners. Things are further complicated by the fact that virtually every cell expresses numerous G proteins, several GRK subtypes, and two non-visual arrestins with distinct signaling capabilities. Finally, novel screening methods for measuring ligand bias must be devised, as the existing methods are not specific for one particular branch of signaling.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare no conflict of interest.
Figures



Similar articles
-
G protein-coupled receptor interactions with arrestins and GPCR kinases: The unresolved issue of signal bias.J Biol Chem. 2022 Sep;298(9):102279. doi: 10.1016/j.jbc.2022.102279. Epub 2022 Jul 19. J Biol Chem. 2022. PMID: 35863432 Free PMC article. Review.
-
Flavors of GPCR signaling bias.Neuropharmacology. 2024 Dec 15;261:110167. doi: 10.1016/j.neuropharm.2024.110167. Epub 2024 Sep 19. Neuropharmacology. 2024. PMID: 39306191 Review.
-
How Ligands Achieve Biased Signaling toward Arrestins.Biochemistry. 2025 Mar 4;64(5):967-977. doi: 10.1021/acs.biochem.4c00843. Epub 2025 Feb 12. Biochemistry. 2025. PMID: 39943784 Review.
-
G protein-coupled receptor kinases (GRKs) orchestrate biased agonism at the β2-adrenergic receptor.Sci Signal. 2018 Aug 21;11(544):eaar7084. doi: 10.1126/scisignal.aar7084. Sci Signal. 2018. PMID: 30131371
-
GRKs as Modulators of Neurotransmitter Receptors.Cells. 2020 Dec 31;10(1):52. doi: 10.3390/cells10010052. Cells. 2020. PMID: 33396400 Free PMC article. Review.
Cited by
-
Therapeutic Opportunities and Challenges in Targeting the Orphan G Protein-Coupled Receptor GPR35.ACS Pharmacol Transl Sci. 2020 Jul 29;3(5):801-812. doi: 10.1021/acsptsci.0c00079. eCollection 2020 Oct 9. ACS Pharmacol Transl Sci. 2020. PMID: 33073184 Free PMC article. Review.
-
VIP plasma levels associate with survival in severe COVID-19 patients, correlating with protective effects in SARS-CoV-2-infected cells.J Leukoc Biol. 2022 May;111(5):1107-1121. doi: 10.1002/JLB.5COVA1121-626R. Epub 2022 Mar 24. J Leukoc Biol. 2022. PMID: 35322471 Free PMC article.
-
GPCR binding and JNK3 activation by arrestin-3 have different structural requirements.bioRxiv [Preprint]. 2023 May 1:2023.05.01.538990. doi: 10.1101/2023.05.01.538990. bioRxiv. 2023. Update in: Cells. 2023 Jun 06;12(12):1563. doi: 10.3390/cells12121563. PMID: 37205393 Free PMC article. Updated. Preprint.
-
Higher-order transient membrane protein structures.Proc Natl Acad Sci U S A. 2025 Jan 7;122(1):e2421275121. doi: 10.1073/pnas.2421275121. Epub 2024 Dec 31. Proc Natl Acad Sci U S A. 2025. PMID: 39739811 Free PMC article.
-
Adrenoceptor Desensitization: Current Understanding of Mechanisms.Pharmacol Rev. 2024 May 2;76(3):358-387. doi: 10.1124/pharmrev.123.000831. Pharmacol Rev. 2024. PMID: 38697858 Free PMC article. Review.
References
-
- Ahn S, Shenoy SK, Wei H, & Lefkowitz RJ (2004). Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J Biol Chem, 279, 35518–35525. - PubMed
-
- Ahn S, Wei H, Garrison TR, & Lefkowitz RJ (2004). Reciprocal regulation of angiotensin receptor-activated extracellular signal-regulated kinases by beta-arrestins 1 and 2. J Biol Chem, 279, 7807–7811. - PubMed
-
- Amarandi R-M, Hjortø GM, Rosenkilde MM, & Karlshøj S (2016). Chapter Eight - Probing Biased Signaling in Chemokine Receptors In Handel TM (Ed.), Methods in Enzymology (Vol. 570, pp. 155–186): Academic Press. - PubMed
-
- Anthony DF, Sin YY, Vadrevu S, Advant N, Day JP, Byrne AM, Lynch MJ, Milligan G, Houslay MD, & Baillie GS (2011). β-Arrestin 1 inhibits the GTPase-activating protein function of ARHGAP21, promoting activation of RhoA following angiotensin II type 1A receptor stimulation. Mol Cell Biol, 31, 1066–1075. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources